Hologic, Inc. (NASDAQ:HOLX) Shares Sold by Kentucky Retirement Systems

Kentucky Retirement Systems decreased its position in Hologic, Inc. (NASDAQ:HOLX) by 1.4% in the 4th quarter, Holdings Channel.com reports. The fund owned 15,961 shares of the medical equipment provider’s stock after selling 220 shares during the period. Kentucky Retirement Systems’ holdings in Hologic were worth $1,151,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also made changes to their positions in HOLX. Covestor Ltd lifted its stake in Hologic by 23.8% during the third quarter. Covestor Ltd now owns 692 shares of the medical equipment provider’s stock worth $56,000 after purchasing an additional 133 shares during the last quarter. First Horizon Advisors Inc. lifted its position in shares of Hologic by 38.3% in the 3rd quarter. First Horizon Advisors Inc. now owns 484 shares of the medical equipment provider’s stock worth $39,000 after buying an additional 134 shares during the last quarter. Brooklyn Investment Group boosted its holdings in shares of Hologic by 14.7% in the 4th quarter. Brooklyn Investment Group now owns 1,131 shares of the medical equipment provider’s stock valued at $82,000 after buying an additional 145 shares during the period. Empirical Finance LLC boosted its holdings in shares of Hologic by 1.8% in the 3rd quarter. Empirical Finance LLC now owns 8,473 shares of the medical equipment provider’s stock valued at $690,000 after buying an additional 147 shares during the period. Finally, Trivant Custom Portfolio Group LLC grew its position in shares of Hologic by 2.1% during the 4th quarter. Trivant Custom Portfolio Group LLC now owns 8,348 shares of the medical equipment provider’s stock valued at $602,000 after buying an additional 169 shares during the last quarter. 94.73% of the stock is currently owned by institutional investors.

Insider Transactions at Hologic

In other Hologic news, COO Essex D. Mitchell sold 24,856 shares of the company’s stock in a transaction on Wednesday, December 4th. The stock was sold at an average price of $76.34, for a total value of $1,897,507.04. Following the transaction, the chief operating officer now owns 27,957 shares of the company’s stock, valued at approximately $2,134,237.38. This represents a 47.06 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 1.88% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on HOLX shares. Mizuho decreased their target price on Hologic from $90.00 to $87.00 and set an “outperform” rating for the company in a research note on Tuesday, November 5th. Leerink Partners lowered Hologic from an “outperform” rating to a “market perform” rating and reduced their price objective for the company from $80.00 to $75.00 in a research report on Thursday, February 6th. Raymond James reaffirmed an “outperform” rating and issued a $90.00 target price (down from $95.00) on shares of Hologic in a research report on Thursday, February 6th. Stephens reiterated an “overweight” rating and issued a $84.00 target price on shares of Hologic in a research note on Thursday, February 6th. Finally, JPMorgan Chase & Co. upped their price target on shares of Hologic from $92.00 to $94.00 and gave the stock an “overweight” rating in a research report on Tuesday, November 5th. Ten equities research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, Hologic has a consensus rating of “Moderate Buy” and an average target price of $85.77.

Hologic Stock Up 0.2 %

HOLX stock opened at $64.47 on Monday. The firm’s 50-day moving average is $69.91 and its two-hundred day moving average is $76.53. The company has a market capitalization of $14.47 billion, a price-to-earnings ratio of 20.34, a price-to-earnings-growth ratio of 2.14 and a beta of 0.98. Hologic, Inc. has a 52 week low of $62.69 and a 52 week high of $84.67. The company has a current ratio of 3.49, a quick ratio of 2.78 and a debt-to-equity ratio of 0.52.

Hologic (NASDAQ:HOLX) last issued its quarterly earnings results on Wednesday, February 5th. The medical equipment provider reported $1.03 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.02 by $0.01. Hologic had a return on equity of 19.72% and a net margin of 18.42%. On average, analysts forecast that Hologic, Inc. will post 4.28 earnings per share for the current fiscal year.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.